U.K. declines to prosecute GSK over paroxetine data
Executive Summary
A criminal investigation of whether GlaxoSmithKline delayed informing MHRA about safety issues associated with use of Seroxat (paroxetine) in patients under 18 years ends March 6 with no action against the firm. Government prosecutors conclude "there is no realistic prospect of a conviction" because laws in effect at the time were not sufficiently strong or comprehensive. Then-New York Attorney General Eliot Spitzer called GSK on its delayed reporting of the pediatric safety of paroxetine, marketed in the U.S. as Paxil, in a 2004 suit. GSK settled by agreeing to post summaries of studies for all its products on the Internet (1"The Pink Sheet," Sept. 6, 2004, p. 11)